CN101990435A - Toll样受体3的选择性激动剂 - Google Patents

Toll样受体3的选择性激动剂 Download PDF

Info

Publication number
CN101990435A
CN101990435A CN2009801126292A CN200980112629A CN101990435A CN 101990435 A CN101990435 A CN 101990435A CN 2009801126292 A CN2009801126292 A CN 2009801126292A CN 200980112629 A CN200980112629 A CN 200980112629A CN 101990435 A CN101990435 A CN 101990435A
Authority
CN
China
Prior art keywords
poly
tlr3
cells
study subject
transformant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801126292A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·A·卡特
大卫·斯特雷耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIM Immunotech Inc
Original Assignee
Hemispherx Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemispherx Biopharma Inc filed Critical Hemispherx Biopharma Inc
Publication of CN101990435A publication Critical patent/CN101990435A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801126292A 2008-02-15 2009-02-17 Toll样受体3的选择性激动剂 Pending CN101990435A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2930708P 2008-02-15 2008-02-15
US61/029,307 2008-02-15
US5160608P 2008-05-08 2008-05-08
US61/051,606 2008-05-08
PCT/US2009/000959 WO2009102496A2 (en) 2008-02-15 2009-02-17 Selective agonist of toll-like receptor 3

Publications (1)

Publication Number Publication Date
CN101990435A true CN101990435A (zh) 2011-03-23

Family

ID=40957440

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801126292A Pending CN101990435A (zh) 2008-02-15 2009-02-17 Toll样受体3的选择性激动剂

Country Status (11)

Country Link
US (1) US20100310600A1 (https=)
EP (1) EP2249845A4 (https=)
JP (1) JP2011525169A (https=)
KR (1) KR20100126390A (https=)
CN (1) CN101990435A (https=)
AU (1) AU2009215128A1 (https=)
BR (1) BRPI0907515A2 (https=)
CA (1) CA2715293A1 (https=)
NZ (1) NZ587371A (https=)
WO (1) WO2009102496A2 (https=)
ZA (1) ZA201005826B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108498362A (zh) * 2018-04-17 2018-09-07 睿欧生物科技（上海）有限公司 预防及治疗口腔溃疡的Toll样受体激动剂漱口水
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2349288A4 (en) * 2008-10-10 2012-08-08 Hemispherx Biopharma Inc TREATMENT OF CHRONIC EXHAUST SYNDROME BY SELECTIVE TOLL LIKE RECEPTOR 3 (TLR3) AGONISTS
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) * 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
NZ599677A (en) * 2009-12-18 2014-10-31 Bavarian Nordic As Production of ifn-lambda by conventional dendritic cells and uses thereof
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
CN115487302A (zh) * 2022-11-09 2022-12-20 吉林大学 Toll样受体3在治疗华支睾吸虫性肝纤维化的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
US5063209A (en) * 1985-08-26 1991-11-05 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAs
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
CA1315229C (en) * 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
US5258369A (en) * 1988-08-29 1993-11-02 Hem Pharmaceuticals Corporation Treatment of chronic cerebral dysfunction by dsRNA methodology
GB0119346D0 (en) * 2001-08-08 2001-10-03 Bioclones Proprietary Ltd Process for the maturation of dendritic cells
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
AU2006322073A1 (en) * 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
AU2007280690C1 (en) * 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
EP2134172A4 (en) * 2007-03-05 2011-06-01 Univ Utah State RESTRICTIVE AGONIST OF THE TOLL LIKE RECEPTOR 3
JP2011518116A (ja) * 2008-02-21 2011-06-23 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション トール様受容体３拮抗薬としての超小型ｒｎａ
EP2349288A4 (en) * 2008-10-10 2012-08-08 Hemispherx Biopharma Inc TREATMENT OF CHRONIC EXHAUST SYNDROME BY SELECTIVE TOLL LIKE RECEPTOR 3 (TLR3) AGONISTS
US20100160413A1 (en) * 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US8722874B2 (en) * 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20120004290A1 (en) * 2009-03-13 2012-01-05 David Strayer Treating chronic fatigue syndrome and prolonged qt interval

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN B. GOWEN ET AL.: ""TLR3 Is Essential for the Induction of Protective Immunity against Punta Toro Virus Infection by the Double-Stranded RNA (dsRNA), Poly(I:C12U), but not Poly(I:C): Differential Recognition of Synthetic dsRNA Molecules"", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108853144A (zh) * 2017-05-16 2018-11-23 科济生物医药（上海）有限公司 Toll样受体激动剂与免疫效应细胞的联用
CN108498362A (zh) * 2018-04-17 2018-09-07 睿欧生物科技（上海）有限公司 预防及治疗口腔溃疡的Toll样受体激动剂漱口水

Also Published As

Publication number Publication date
AU2009215128A1 (en) 2009-08-20
NZ587371A (en) 2012-12-21
ZA201005826B (en) 2011-10-26
WO2009102496A3 (en) 2009-11-05
EP2249845A2 (en) 2010-11-17
EP2249845A4 (en) 2012-02-29
JP2011525169A (ja) 2011-09-15
BRPI0907515A2 (pt) 2015-07-28
KR20100126390A (ko) 2010-12-01
WO2009102496A2 (en) 2009-08-20
CA2715293A1 (en) 2009-08-20
US20100310600A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
Krieg Therapeutic potential of Toll-like receptor 9 activation
Hussein et al. Toll-like receptor agonists: a patent review (2011–2013)
Hedayat et al. Prophylactic and therapeutic implications of toll‐like receptor ligands
CN101990435A (zh) Toll样受体3的选择性激动剂
JP2020143165A (ja) 免疫刺激組成物およびその使用方法
JP5161770B2 (ja) 免疫刺激オリゴヌクレオチド及びその医薬用途
AU2008223446B2 (en) Restrictive agonist of Toll-like receptor 3 (TLR3)
US9315538B2 (en) Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
JP2002500159A (ja) 抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
CN114762695A (zh) 具有免疫增强活性的包含寡核苷酸的复合体及其用途
JP2002510644A (ja) 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
US20260015390A1 (en) Cpg amphiphiles and uses thereof
WO2005083076A1 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
JP2010530005A (ja) Ｔｎｆ−ｒアゴニスト療法レジメンの毒性を緩和するためのｔｌｒアゴニスト及び／又は１型インターフェロンの使用
AU2009308105B2 (en) Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
CN1307196C (zh) 具有改善的免疫调节功能的经修饰的CpG寡聚脱氧核苷酸
JP6536964B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
Tomai et al. TLR agonists as vaccine adjuvants
EP1657307A1 (en) Oligonucleotides that induce the secretion of GM-CSF
CN111164104A (zh) 白蛋白结合肽缀合物及其方法
WO2008065752A1 (fr) Agent immunothérapeutique contenant un arndi en tant que principe actif
JP2020510052A (ja) 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用
KR102478043B1 (ko) 항원 전달용 조성물
WO2021081043A1 (en) Mucus penetrating particle compositions and methods of use thereof enhancing immune response
HK40045177B (en) Cpg amphiphiles and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110323